APA (7th ed.) Citation

Zhao, X., Zhang, J., Qiu, L., Han, Q., Yan, X., Zhu, Y., . . . Sun, S. (2025). Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A prospective, single-arm, phase II trial. BMC Medicine, 23(1), 1. https://doi.org/10.1186/s12916-025-04385-4

Chicago Style (17th ed.) Citation

Zhao, Xiao, et al. "Efficacy, Safety, and Exploratory Biomarker Analysis of Envafolimab Plus Carboplatin and Etoposide as First-line Treatment for Extensive-stage Small-cell Lung Cancer: A Prospective, Single-arm, Phase II Trial." BMC Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12916-025-04385-4.

MLA (9th ed.) Citation

Zhao, Xiao, et al. "Efficacy, Safety, and Exploratory Biomarker Analysis of Envafolimab Plus Carboplatin and Etoposide as First-line Treatment for Extensive-stage Small-cell Lung Cancer: A Prospective, Single-arm, Phase II Trial." BMC Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12916-025-04385-4.